Discovering orphan receptor function using human in vitro pharmacology

Current Opinion in Pharmacology

Volumn 3, Issue 2, 2003, Pages 135-139

  Maguire, Janet J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; ENDOTHELIN 1; GHRELIN; GROWTH HORMONE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; RECEPTOR BLOCKING AGENT; RELAXIN; SOMATOMEDIN C; UROTENSIN II;

ARTERY; CARDIOVASCULAR DISEASE; DISEASE MARKER; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TARGETING; GENE FUNCTION; GROWTH HORMONE RELEASE; HEART FAILURE; HEART MUSCLE; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; VASOCONSTRICTION; VASODILATATION; VEIN;

ANIMALS; CARDIOVASCULAR SYSTEM; CARRIER PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PEPTIDE HORMONES; RECEPTORS, PEPTIDE; RELAXIN; UROTENSINS;

EID: 0037384207     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(03)00006-7     Document Type: Review

References (47)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW et al.: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999, 401:282-286.
2. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660.
3. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukudumi S, Hinuma S, Kitada C et al.: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998, 251:471-476.
4. Katugampola SD, Kuc RE, Maguire JJ, Davenport AP: G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors. Clin Sci 2002, 103(Suppl 1):171S-175S.
5. Katugampola SD, Maguire JJ, Kuc RE, Wiley KE, Davenport AP: Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. Can J Physiol Pharmacol 2002, 80:369-374.
6. Oksenberg D, Marsters SA, O'Dowd BF, Jin H, Havlik S, Peroutka SJ, Ashkenazi A: A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature 1992, 360:161-163.
7. Maguire JJ, Davenport AP: Endothelin receptor expression and pharmacology in human saphenous vein graft. Br J Pharmacol 1999, 126:443-450.
8. Maguire JJ, Davenport AP: Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease. Br J Pharmacol 1998, 125:238-240.
9. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN: Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000, 131:1262-1274.
10. Maguire JJ, Davenport AP: Is urotensin-II the new endothelin? Br J Pharmacol 2002, 137:579-588.
11. MacLean MR, Alexander D, Stirratt A, Gallagher M, Douglas SA, Ohlstein EH, Morecroft I, Polland K: Contractile responses to human urotensin-II in rat and human pulmonary arteries: effects of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 2000, 130:201-204.
12. Maguire JJ, Kuc RE, Davenport AP: Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000, 131:441-446.
13. Stirrat A, Gallagher M, Douglas SA, Olhstein EH, Berry C, Kirk A: Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol 2001, 280:H925-H928.
14. Russell FD, Molenaar P, O'Brien DM: Cardiostimulant effects of human urotensin-II in human heart in vitro. Br J Pharmacol 2001, 132:5-9.
15. Behm DJ, Herold CL, Ohlstein EH, Knight SD, Dhanak D, Douglas SA: Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br J Pharmacol 2002, 137:449-458.
16. Camarda V, Guerrini R, Kostenis E, Rizzi A, Calo G, Hattenberger A, Zucchini M, Salvadori S, Regoli D: A new ligand for urotensin-II receptor. Br J Pharmacol 2002, 137:311-314.
17. Flohr S, Kurz M, Kostenis E, Brkovich A, Fournier A, Klabunde T: Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 2002, 45:1799-1805.
18. Böhm F, Pernow J: Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002, 135:25-27.
19. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, Mori K, Komatsu Y, Usui T, Shimatsu A et al.: Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000, 85:4908-4911.
20. Peino R, Baldelli R, Rodriguez-Garcia J, Rodriguez-Segade S, Kojima M, Kangawa K, Arvat E, Ghigo E, Dieguez C, Casanueva FF: Ghrelin-induced growth hormone secretion in humans. Eur J Endocrinol 2000, 143:R11-R14.
21. Wren AM, Seal LJ, Cohen MA, Byrnes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR: Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001, 86:5992.
22. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS: A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001, 50:1714-1719.
23. Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL, Heiman ML, Lehnert P, Fichter M, Tschop M: Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001, 145:669-673.
24. Hansen TK, Dall R, Hosoda H, Kojima M, Kangawa K, Christiansen JS, Jorgensen JO: Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol 2002, 56:203-206.
25. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB, Korbonits M: The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002, 87:2988-2991.
26. 9]-Ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with atherosclerosis. Br J Pharmacol 2001, 134:143-149.
27. Papotti M, Ghè C, Cassoni P, Catapano F, Deghenghi R, Ghigo E, Mucciolo G: Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 2000, 85:3803-3807.
28. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, Hayashi Y, Kangawa K: Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol 2001, 280:R1483-R1487.
29. Nagaya N, Miyatake K, Uematsu M, Oya H, Shimizu W, Hosoda H, Kojima M, Nakanishi N, Mori H, Kangawa K: Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab 2001, 86:5854-5859.
30. Napoli R, Guardasole V, Matarazzo M, Palmieri EA, Oliviero U, Fazio S, Saccà L: Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol 2002, 39:90-95.
31. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Saccà L: A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996, 334:809-814.
32. Wiley KE, Davenport AP: Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 2002, 136:1146-1152.
33. Bacon CR, Cary NRB, Davenport AP: Endothelin peptide and receptors in human atherosclerotic coronary artery. Circ Res 1996, 79:794-801.
34. Lerman A, Edwards BS, Hallett JW, Hublein DM, Sandberg SM, Burnett JC: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991, 325:997-1001.
35. Katugampola SD, Davenport AP: Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. Br J Pharmacol 2001, 134:1385-1392.
36. Katugampola SD, Davenport AP: Changes in ETA-, AT(1)- and AT(2)-receptors in the phenotypically transformed intimal smooth muscle layer of human atherosclerotic coronary arteries. J Cardiovasc Pharmacol 2000, 36(Suppl 1):S395-S396.
37. Okumura H, Nagaya N, Enomoto M, Nakagawa E, Oya H, Kangawa K: Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol 2002, 39:779-783.
38. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, George SR, Nguyen T: A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993, 136:355-360.
39. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, Osmond DH, George SR, O'Dowd BF: Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000, 74:34-41.
40. 1)apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role. Br J Pharmacol 2001, 132:1255-1260.
41. Tatemoto K, Takayama K, Zou M-X, Kumaki I, Zhang W, Kumano K, Fujimiya M: The novel peptide apelin lowers blood pressure via a nitric oxide-depedent mechanism. Regul Pept 2001, 99:87-92.
42. Szokodi I, Tavi P, Földes G, Voutilainen-Myllylä S, Ilves M, Tokola H, Pikkarainen S, Piuhola J, Rysä J, Tóth M, Ruskoaho H: Apelin, a novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002, 91:434-440.
43. Hsu SY, Kudo M, Chen T, Nakabayashi K, Bhalla A, van der Spek PJ, van Duin M, Hsueh AJW: The three subfamilies of leucinerich repeat-containing G-protein-coupled receptors (LGR): identification of LGR6 and LGR7 and the signaling mechanism for LGR7. Mol Endocrinol 2000, 14:1257-1271.
44. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, Hsueh AJW: Activation of orphan receptors by the hormone relaxin. Science 2002, 295:671-674.
45. Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster FP, Baumann G, Stangl K: The pregnancy hormone relaxin is a player in human heart failure. FASEB J 2001, 15:2187-2195.
46. Fisher C, MacLean M, Morecroft I, Seed A, Johnston F, Hillier C, McMurray J: Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? Circulation 2002, 106:292-295.
47. Petersen LK, Svane D, Uldbjerg N, Forman A: Effects of human relaxin on isolated rat and human myometrium and uteroplacental arteries. Obst Gynecol 1991, 78:757-762.